收费全文 | 2413272篇 |
免费 | 199233篇 |
国内免费 | 4222篇 |
耳鼻咽喉 | 34807篇 |
儿科学 | 74304篇 |
妇产科学 | 64101篇 |
基础医学 | 340988篇 |
口腔科学 | 69324篇 |
临床医学 | 218691篇 |
内科学 | 472764篇 |
皮肤病学 | 48867篇 |
神经病学 | 205298篇 |
特种医学 | 98012篇 |
外国民族医学 | 902篇 |
外科学 | 365980篇 |
综合类 | 56398篇 |
一般理论 | 1049篇 |
预防医学 | 195380篇 |
眼科学 | 56360篇 |
药学 | 180808篇 |
4篇 | |
中国医学 | 4399篇 |
肿瘤学 | 128291篇 |
2018年 | 25169篇 |
2017年 | 19658篇 |
2016年 | 21511篇 |
2015年 | 24374篇 |
2014年 | 35313篇 |
2013年 | 53103篇 |
2012年 | 72367篇 |
2011年 | 75896篇 |
2010年 | 44330篇 |
2009年 | 42760篇 |
2008年 | 71856篇 |
2007年 | 76278篇 |
2006年 | 77017篇 |
2005年 | 74841篇 |
2004年 | 71780篇 |
2003年 | 69250篇 |
2002年 | 68257篇 |
2001年 | 113827篇 |
2000年 | 117709篇 |
1999年 | 99047篇 |
1998年 | 26857篇 |
1997年 | 24323篇 |
1996年 | 24253篇 |
1995年 | 24936篇 |
1994年 | 23492篇 |
1993年 | 21849篇 |
1992年 | 80223篇 |
1991年 | 77226篇 |
1990年 | 74368篇 |
1989年 | 71599篇 |
1988年 | 66507篇 |
1987年 | 65438篇 |
1986年 | 61941篇 |
1985年 | 59018篇 |
1984年 | 44627篇 |
1983年 | 37982篇 |
1982年 | 23045篇 |
1981年 | 20447篇 |
1979年 | 41609篇 |
1978年 | 29175篇 |
1977年 | 24449篇 |
1976年 | 22845篇 |
1975年 | 24048篇 |
1974年 | 29731篇 |
1973年 | 28181篇 |
1972年 | 26403篇 |
1971年 | 24357篇 |
1970年 | 22893篇 |
1969年 | 21215篇 |
1968年 | 19251篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献